Myelofibrosis
📧 Sign up to get email alerts when something new happens for Myelofibrosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) [Phase 3]
Phase 3 LIMBER-304 trial evaluating parsaclisib with ruxolitinib in myelofibrosis patients with suboptimal response to ruxolitinib was termi…
-
CLINICAL_TRIALS research · 2024-08-12Clinical Trial Update: Myeloproliferative Neoplastic Diseases Observatory From Brest
A Brest-based clinical trial observatory update for myeloproliferative neoplasms, enrolling patients with polycythemia vera, essential throm…
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias [Phase 1, Phase 2]
An early-phase study of escalating doses of AT9283 for various leukemias has been terminated.
-
FDA approval · 2024-07-30FDA Approved: INREBIC — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for INREBIC (fedratinib hydrochloride) from Celgene Corporation (NDA 212327).
-
CLINICAL_TRIALS trial_result · 2024-06-27Clinical Trial Update: TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea [Phase 1]
This Phase 1 trial evaluated the combination of TGR-1202 and ruxolitinib in patients with myelofibrosis and polycythemia vera who are resist…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-05-29Clinical Trial Update: Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients [Phase 2]
Phase 2 feasibility study evaluating apixaban for thromboprophylaxis in patients with JAK2-positive myeloproliferative neoplasms (including …
-
CLINICAL_TRIALS research · 2024-05-10Clinical Trial Update: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis [Phase 2]
Phase 2 study of TL-895 in patients with myelofibrosis or indolent systemic mastocytosis is currently recruiting.
-
CLINICAL_TRIALS other · 2024-05-06Clinical Trial Update: Expanded Access to Navitoclax
Expanded access program for Navitoclax sponsored by AbbVie for myelofibrosis, acute lymphoblastic leukemia, and lymphoblastic lymphoma is no…
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition [Phase 1]
A Phase 1 clinical trial at Fox Chase Cancer Center tests the combination of pacritinib and talazoparib in myeloproliferative neoplasms unre…
-
CLINICAL_TRIALS trial_result · 2024-05-01Clinical Trial Update: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis [Phase 2]
Phase 2 study of INCB050465 in combination with ruxolitinib for myelofibrosis. The trial was terminated and results were posted in May 2024.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis [Phase 2]
Phase 2 clinical trial evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of oral GB2064 in participants with myelofibr…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial update evaluating topotecan hydrochloride and carboplatin with or without veliparib for advanced myeloproliferative disorders …
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer [Phase 2]
Phase 2 study evaluating a conditioning regimen of fludarabine phosphate, cyclophosphamide, and total body irradiation followed by donor ste…
-
CLINICAL_TRIALS trial_result · 2024-03-05Clinical Trial Update: JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis [Phase 2]
A Phase 2 clinical trial investigating a JAK inhibitor given before donor stem cell transplantation in patients with primary or secondary my…
-
CLINICAL_TRIALS trial_result · 2024-02-07Clinical Trial Update: Actuate 1901: 9-ING-41 in Myelofibrosis [Phase 2]
Phase 2 clinical trial update for 9-ING-41 in myelofibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2024-01-30Clinical Trial Update: An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib [Phase 3]
A Phase 3 trial evaluating fedratinib versus best available therapy in high- or intermediate-risk myelofibrosis subtypes after ruxolitinib f…
-
CLINICAL_TRIALS trial_result · 2024-01-10Clinical Trial Update: Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) [Phase 1, Phase 2]
Clinical trial update for Bomedemstat (IMG-7289/MK-3543) in myelofibrosis showing completion and posted results for Phase 1/2 study.
-
CLINICAL_TRIALS trial_result · 2024-01-08Clinical Trial Update: Myeloproliferative Neoplasms: an In-depth Case-control Study
A completed clinical trial examining myeloproliferative neoplasms with results posted; focuses on Polycythemia Vera, Essential Thrombocythem…
-
CLINICAL_TRIALS trial_result · 2023-12-15Clinical Trial Update: Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia [Phase 2]
A Phase 2 trial evaluating fostamatinib alone or with ruxolitinib for myelofibrosis patients with severe thrombocytopenia has been terminate…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis [Phase 3]
A Phase 3 trial comparing jaktinib to hydroxyurea in intermediate-2 or high-risk myelofibrosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-03Clinical Trial Update: Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. [Phase 2]
Phase 2 trial update of Jaktinib in relapsed/refractory myelofibrosis patients previously treated with ruxolitinib has completed.
-
CLINICAL_TRIALS trial_result · 2023-10-31Clinical Trial Update: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) [Phase 1, Phase 2]
Phase 1/2 trial evaluating panobinostat and ruxolitinib in myelofibrosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-09-28Clinical Trial Update: Methods of T Cell Depletion Trial (MoTD) [Phase 2]
Phase 2 trial update for methods of T cell depletion in various hematologic malignancies is ongoing.
-
FDA approval · 2023-09-15FDA Approved: OJJAARA — Original Application (GlaxoSmithKline LLC)
FDA approved OJJAARA (momelotinib) from GlaxoSmithKline in an original application for the treatment of myelofibrosis.
-
CLINICAL_TRIALS trial_result · 2023-09-13Clinical Trial Update: Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation [Phase 2]
Phase 2 study evaluating a combination of Itacitinib, Tacrolimus, and Sirolimus for prevention of graft-versus-host disease in patients with…